The US Food and Drug Administration (FDA) has approved a 4-week dosing schedule for nivolumab (Opdivo) across several indications, including renal cell carcinoma (RCC). In America, doctors can now prescribe the new dosing schedule of 480 mg of nivolumab infused every 30 minutes every 4 weeks.

This change in dosing schedule has not yet been approved by the European Medicines Agency (EMA) for use in Europe, and is yet to go through the National Institute for Health and Care Excellence (NICE) appraisal process for England and Wales.

If this change to the dosing regime is approved in Europe, this could make life a lot easier for patients on nivolumab. One infusion a month is far easier to deal with than every fortnight, especially if people are travelling long distances to regional hospitals to receive their treatment. We will keep you updated with any news about the approval of this dosing regime in the UK.

Read more in OncLive here